celecoxib has been researched along with Diarrhea in 15 studies
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 9.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| " Glutamine may decrease chemotherapy-associated diarrhea." | 9.11 | A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005) |
| "NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk." | 7.73 | Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| " There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo." | 6.53 | Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 5.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "The combination of celecoxib with docetaxel and irinotecan did not ameliorate irinotecan-induced diarrhea." | 5.11 | A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. ( Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP, 2005) |
| " Glutamine may decrease chemotherapy-associated diarrhea." | 5.11 | A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005) |
| "While irinotecan (CPT-11) has a potent anti-cancer effect, it also causes serious diarrhea as an adverse reaction." | 3.88 | CPT-11-Induced Delayed Diarrhea Develops via Reduced Aquaporin-3 Expression in the Colon. ( Fujikawa, T; Ikarashi, N; Kato, S; Kimura, H; Kon, R; Machida, Y; Matsunaga, Y; Minami, M; Murakami, Y; Sakurai, R; Sugiyama, K; Tomimoto, R; Tsubota, Y, 2018) |
| "NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk." | 3.73 | Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| "Celecoxib dosage was fixed." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| "This multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessed renal function during dosing with etoricoxib 90 mg daily, celecoxib 200 mg twice daily, and naproxen 500 mg twice daily." | 2.73 | Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. ( Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C, 2007) |
| " There was no significant difference in the incidence of adverse events (AEs), SAEs, and discontinuations due to AEs; however, the incidence of gastrointestinal AEs in OA patients treatment with celecoxib is significantly higher than that with placebo." | 2.53 | Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. ( Gu, K; Hou, Y; Xu, C; Yasen, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kon, R | 1 |
| Tsubota, Y | 1 |
| Minami, M | 1 |
| Kato, S | 1 |
| Matsunaga, Y | 1 |
| Kimura, H | 1 |
| Murakami, Y | 1 |
| Fujikawa, T | 1 |
| Sakurai, R | 1 |
| Tomimoto, R | 1 |
| Machida, Y | 1 |
| Ikarashi, N | 1 |
| Sugiyama, K | 1 |
| Moreno-Borque, R | 1 |
| Matito, A | 1 |
| Álvarez-Twose, I | 1 |
| Morgado, JM | 1 |
| Sánchez-Muñoz, L | 1 |
| Orfao, A | 1 |
| Escribano, L | 1 |
| Xu, C | 1 |
| Gu, K | 1 |
| Yasen, Y | 1 |
| Hou, Y | 1 |
| Malik, I | 1 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Garberoglio, C | 1 |
| Trifan, OC | 1 |
| Durham, WF | 1 |
| Salazar, VS | 1 |
| Horton, J | 1 |
| Levine, BD | 1 |
| Zweifel, BS | 1 |
| Davis, TW | 1 |
| Masferrer, JL | 1 |
| Blanke, CD | 1 |
| Mattek, NC | 1 |
| Deloughery, TG | 1 |
| Koop, DR | 1 |
| Bird, S | 1 |
| Dy, GK | 1 |
| Mandrekar, S | 1 |
| Peethambaram, PP | 1 |
| Okuno, SH | 1 |
| Croghan, GC | 1 |
| Hanson, LJ | 1 |
| Furth, A | 1 |
| Adjei, AA | 1 |
| Pan, CX | 1 |
| Loehrer, P | 1 |
| Seitz, D | 1 |
| Helft, P | 1 |
| Juliar, B | 1 |
| Ansari, R | 1 |
| Pletcher, W | 1 |
| Vinson, J | 1 |
| Cheng, L | 1 |
| Sweeney, C | 1 |
| Houmani, Z | 1 |
| Imbert, A | 1 |
| Duchmann, JC | 1 |
| Messerschmitt, C | 1 |
| Barbare, JC | 1 |
| Latrive, JP | 1 |
| Biour, M | 1 |
| Calvo, N | 1 |
| Iversen, E | 1 |
| Munck, LK | 1 |
| Sauter, ER | 1 |
| Qin, W | 1 |
| Schlatter, L | 1 |
| Hewett, JE | 1 |
| Flynn, JT | 1 |
| Schwartz, JI | 1 |
| Thach, C | 1 |
| Lasseter, KC | 1 |
| Miller, J | 1 |
| Hreniuk, D | 1 |
| Hilliard, DA | 1 |
| Snyder, KM | 1 |
| Gertz, BJ | 1 |
| Gottesdiener, KM | 1 |
| Köhne, CH | 1 |
| De Greve, J | 1 |
| Hartmann, JT | 1 |
| Lang, I | 1 |
| Vergauwe, P | 1 |
| Becker, K | 1 |
| Braumann, D | 1 |
| Joosens, E | 1 |
| Müller, L | 1 |
| Janssens, J | 1 |
| Bokemeyer, C | 1 |
| Reimer, P | 1 |
| Link, H | 1 |
| Späth-Schwalbe, E | 1 |
| Wilke, HJ | 1 |
| Bleiberg, H | 1 |
| Van Den Brande, J | 1 |
| Debois, M | 1 |
| Bethe, U | 1 |
| Van Cutsem, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal [NCT00040391] | Phase 2 | 0 participants | Interventional | 2002-06-30 | Terminated | ||
| Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181] | Phase 3 | 86 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Diarrhea
| Article | Year |
|---|---|
Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.
Topics: Abdominal Pain; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Diarrhea; Dyspepsia; Headache; | 2016 |
6 trials available for celecoxib and Diarrhea
| Article | Year |
|---|---|
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyc | 2005 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neo | 2005 |
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agent | 2007 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemot | 2008 |
8 other studies available for celecoxib and Diarrhea
| Article | Year |
|---|---|
CPT-11-Induced Delayed Diarrhea Develops via Reduced Aquaporin-3 Expression in the Colon.
Topics: Animals; Aquaporin 3; Aquaporin 4; Aquaporins; Camptothecin; Celecoxib; Cell Survival; Colon; Cycloo | 2018 |
Response to celecoxib in a patient with indolent systemic mastocytosis presenting with intractable diarrhea.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Diarrhea; Female; Humans; Mastocytosis, Systemic; Middle Age | 2015 |
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colon; Cyclooxygen | 2002 |
An unusual case of diarrhoea.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Colchicine; Diarrhea; Drug Pres | 2005 |
[Acute colitis closely following the beginning of celecoxib treatment].
Topics: Acute Disease; Aged, 80 and over; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Bac | 2005 |
[Intestinal side effects of COX-2 inhibitors].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Diseases; Colonic Pouches; | 2006 |
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Body Fluids; Breast Neoplasms; Car | 2006 |
Celecoxib for arthritis.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyg | 1999 |